

## **GSK Patient Group Funding - 2018**

### **ACCESS**

ACCESS advocates on behalf of members of various Québec ethnic communities for equity and equality in healthcare and social services.

During 2018:

- GSK provided project funding of \$10,000 for the "Augmenter la couverture vaccinale: une action concertée" - Symposium

Our support represented 8% of their overall income.

### **Advocacy Boot Camp**

Advocacy Boot Camp seeks to help patient groups/advocates better understand and navigate the healthcare system to get access to the right treatment at the right time for the right individual. They accomplish this through providing a program based on knowledge transfer and building capacity that is led by a group of selected experts.

During 2018:

- GSK provided project funding of \$15,000 for the Advocacy Boot Camp 2018

Our support represented 8% of their overall income.

### **Asthma Canada**

Asthma Canada seeks to empower every child and adult in Canada with asthma to live an active and symptom-free life. Their mission is to be the balanced voice for asthma in Canada, advancing optimal self-management, prevention, research and healthcare.

During 2018:

- GSK provided core funding of \$88,000 to support Asthma Canada initiatives in 2018
- GSK provided project funding of \$20,000 for the Global Franchises Project grant to support World Asthma Day 2018

Our support represented 11% of their overall income.

### **British Columbia Lung Association**

The British Columbia Lung Association is a long standing and solid patient organization in Canada. Their mission is to improve the lung health of British Columbians through strategic initiatives of research, education and advocacy.

During 2018:

- GSK provided project funding of \$5,000 for a Lung Month Celebration fundraising event

Our support represented 1% of their overall income.

### **Best Medicines Coalition (BMC)**

The Best Medicines Coalition (BMC) is a national alliance of Canadian patient organizations and individual patient advocates who share a commitment to ensuring safe, timely and equitable access to evidence-based medicines for all Canadians. Representing millions of patients living with or affected by chronic disease or other illnesses, the organization is engaged in a range of related policy discussions, including pharmaceutical review, reimbursement, treatment, life cycle management and safety issues.

During 2018:

- GSK provided project funding of \$35,000 for a National Pharmacare Advocacy and Pharmaceutical Patient Access Advocacy Programs

Our support represented 16% of their overall income.

### **Better Pharmacare Coalition (BPC)**

The Better PharmaCare Coalition (BPC) is a joining together of provincial and national health organizations and consumer groups with a mandate to speak on behalf of its 2,000,000-plus members on issues related to the Government of British Columbia's PharmaCare (BC PharmaCare) program. The coalition was formed in 1997 in response to BC PharmaCare policy development not reflective of medical literature, best clinical practice and the needs of patients in BC.

During 2018:

- GSK provided core funding of \$20,000 for Advocacy and Policy Initiatives in British Columbia

Our support represented 8% of their overall income.

### **Canadian Caregiver Network**

The Caregiver Network (TCN) is Canada's largest online learning network supporting family caregivers, their loved ones and the health care professionals who work on their behalf.

During 2018:

- GSK provided project funding of \$25,000 for the Caregiver Advocacy Program - Foresight 20/20

Our support represented 5% of their overall income.

### **Chronic Obstructive Pulmonary Disease (COPD) Canada**

COPD Canada is a non-profit educational society and patient advocacy group focused on providing support for people living with Chronic Obstructive Pulmonary Disease (COPD). Their goal is to increase national public awareness of COPD and to upgrade the information, services and support currently available to patients and their families. The group's long-range objectives include the prevention of COPD as well as enhancing the treatment of COPD through education, patient care and advocacy.

During 2018:

- GSK provided core funding of \$25,000 for COPD Canada initiatives for 2018

Our support represented 8.5% of their overall income.

### **Canadian Organization for Rare Disorders (CORD)**

Canadian Organization for Rare Disorders (CORD) is Canada's national network for organizations representing all those with rare disorders. CORD provides a strong common voice to advocate for health policy and a healthcare system that works for those with rare disorders. CORD works with governments, researchers, clinicians and industry to promote research, diagnosis, treatment and services for all rare disorders in Canada.

During 2018:

- GSK provided a membership fee of \$5,000

Our support represented less than 5% of their overall income.

### **Colorectal Cancer**

Colorectal Cancer Canada is the country's leading non-profit organization dedicated to increasing awareness and educating Canadians about colorectal cancer, supporting patients and their families and advocating on their behalf.

During 2018:

- GSK provided association benefits and sponsorship fee of \$15,000 for a scientific roundtable

Our support represented less than 6% of their overall income.

### **Lung Association of New Brunswick**

The Lung Association of New Brunswick is a charitable organization dedicated to good health through the prevention of lung disease and the promotion of wellness by advocacy, with education, and through research.

During 2018:

- GSK provided project funding of \$22,500 for improving COPD diagnosis rates and community pulmonary rehabilitation

Our support represented 4% of their overall income.

### **Myeloma Canada Research Network**

Myeloma Canada is a non-profit, charitable organization created by, and for people impacted by multiple myeloma, a relatively unknown cancer of the plasma cells. Exclusively devoted to the Canadian myeloma community, Myeloma Canada has been making myeloma matter since 2005. As a patient-driven, patient-focused grassroots organization, Myeloma Canada drives collaborative efforts to unify the voice of the community to effectively shape the Canadian treatment landscape with a committed focus on the improvement of patient outcomes.

During 2018:

- GSK provided association benefits and standard sponsorship fee of \$30,000

Our support represented less than 1% of their overall income.

### **Nova Scotia Lung**

The Lung Association of Nova Scotia's mission is to improve the quality of life by controlling and preventing lung disease through research, advocacy, patient services and education. The Lung Association of Nova Scotia works on chronic disease, infectious disease, tobacco related issues and environmental issues.

During 2018:

- GSK provided project funding of \$30,000 for COPD Health System Analysis

Our support represented 6% of their overall income.

### **Ontario Lung Association (OLA)**

The Ontario Lung Association is a leading not-for-profit health organization focused on the prevention and treatment of lung disease, health promotion activities including: tobacco cessation and prevention, air quality, and support for groundbreaking lung research.

During 2018:

- GSK provided project funding of \$50,000 for the Patient First-Advancing the Lung Health Agenda initiative
- GSK provided project funding of \$25,000 for the Partners in Lung Health Initiative
- GSK provided project funding of \$7,500 for the Breathe! Research Gala
- GSK provided conference sponsorship funding of \$18,955 for the 2018 Better Breathing Conference Ontario

Our support represented 2.7% of their overall income.

### **Pulmonary Hypertension Association of Canada**

The Pulmonary Hypertension Association of Canada (PHA Canada) is a federally registered charity whose mission is to empower the Canadian pulmonary hypertension community through awareness, advocacy, education, research and patient support. PHA Canada has been working to better the lives of Canadians affected by pulmonary hypertension since 2008. PHA Canada represents the Canadian pulmonary hypertension community, which consists of approximately 5,000 patients.

During 2018:

- GSK provided corporate committee dues of \$17,500 for a membership

Our support represented 6% of their overall income.

### **L'Association Pulmonaire du Québec (QLA)**

The Quebec Lung Association is a registered Canadian charity that works on asthma, emphysema, COPD, tuberculosis, sleep apnea, lung diseases, tobacco, smoking-cessation, and air pollution. As a member of the Canadian Lung Association, the International Union against Tuberculosis and Lung Disease, as well as the World Health Organization, the Association has always been deeply involved in the scientific community's relentless fight against tuberculosis.

During 2018:

- GSK provided core funding of \$25,000 for the Pulmonary Rehab Initiative
- GSK provided corporate sponsorship of \$8,500 for the annual fundraising event- Bulles et Tapis Rouge
- GSK provided project funding of \$10,000 for the Annual Immunization Campaign
- GSK provided project funding of \$15,000 for the COPD Concentration Table
- GSK provided project funding of \$35,000 for the World COPD Day Campaign
- GSK provided conference sponsorship funding of \$15,000 for the Conférence en Santé Respiratoire du Québec

Our support represented 0.02% of their overall income.